HCA Holdings Inc.
Thesis
HCA is well-positioned to benefit from significant industry tailwinds, particularly from the growing Medicare eligible population, which is expected to increase at a CAGR of ~3.0% over the next 20 years. The company's strong free cash flow allows for opportunistic share repurchases, and management has already returned $7 billion to shareholders, highlighting their commitment to returning capital. Additionally, health care reform is expected to reduce the number of unprofitable uninsured patients, potentially adding $1 billion in EBITDA over the next two years.
Did it work?
Without specific price performance data or a defined time frame since the pitch, it's difficult to assess whether the thesis has played out. The thesis outlines several positive catalysts, such as industry tailwinds and shareholder returns, but without knowing if these have materialized or how the stock has performed, the outcome remains uncertain.
Raw excerpt
No raw excerpt stored.